KB-1274

Human IgG4-S228P kappa, isotype control

×
Please enable JavaScript in your browser to complete this form.
33721
Home » Antibodies » Human IgG4-S228P kappa, isotype control

Background of Human IgG4-S228P kappa, isotype control

Isotype controls are a type of primary antibodies that lack specificity to the target, but match the class and type of the primary antibody used in in vitro and in vivo studies. Isotype controls are often used to measure the level of non-specific background signal caused by binding non-specifically to Fc receptors on the cell surface, or other cellular molecules. Chinese hamster ovary (CHO) host cell line is the most popular mammalian system of therapeutic proteins production. The isotype controls produced by CHO line share similar posttranslational modifications with the therapeutic proteins, especially in N‐linked glycosylation, which are useful benchmark in the discovery and development of therapeutic antibodies.

Specifications

Catalog NumberKB-1274
Antibody NameHuman IgG4-S228P kappa, isotype control
IsotypeHuman IgG4-S228P, kappa
TargetHEL
Species ReactivityChicken
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Vidarsson, G., Dekkers, G. & Rispens, T. IgG Subclasses and Allotypes: From Structure to Effector Functions. Front. Immunol. 5, (2014).
  2. Zhong, X. et al. Transient CHO expression platform for robust antibody production and its enhanced N-glycan sialylation on therapeutic glycoproteins. Biotechnol. Prog. 35, e2724 (2019).
Please enable JavaScript in your browser to complete this form.